Merck, 69053-3, BLR(DE3) Competent Cells - Novagen

General description
BLR is a recA⁻ derivative of BL21 that improves plasmid monomer yields and may help stabilize target plasmids containing repetitive sequences or whose products may cause the loss of the DE3 prophage (1, 2).

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
Genotype: F⁻ompT hsdSB(rB⁻ mB⁻) gal lac ile dcm Δ(srl-recA)i306::Tn10 (tetR)(DE3)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
BLR is a recA derivative of BL21 that improves plasmid monomer yields and may help stabilize target plasmids containing repetitive sequences.
Other Notes
1. A. Roca (U. of Wisconsin), personal
communication.

2. Studier, F. W. (1991) J. Mol. Biol. 219,
37-44.
0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlBLR(DE3) Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

Legal Information
NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Multiple Toxicity Values, refer to MSDS (O)